Discovery of plasma biomarkers for Parkinson's disease diagnoses based on metabolomics and lipidomics  

作　　者：Xiaoxiao Wang Bolun Wang Fenfen Ji Jie Yan Jiacheng Fang Doudou Zhang Ji Xu Jing Ji Xinran Hao Hemi Luan Yanjun Hong Shulan Qiu Min Li Zhu Yang Wenlan Liu Xiaodong Cai Zongwei Cai 

机构地区：[1]State Key Laboratory of Environmental and Biological Analysis,Department of Chemistry,Hong Kong Baptist University,Hong Kong,China [2]Department of Neurosurgery,Shenzhen Key Laboratory of Neurosurgery,the First Affiliated Hospital of Shenzhen University,Shenzhen Second People's Hospital,Shenzhen 518035,China [3]The Central Laboratory,the First Affiliated Hospital of Shenzhen University,Shenzhen Second People's Hospital,Shenzhen 518035,China [4]Mr.and Mrs.Ko Chi Ming Centre for Parkinson's Disease Research,School of Chinese Medicine,Hong Kong Baptist University,Hong Kong,China

出　　处：《Chinese Chemical Letters》2024年第11期260-265,共6页中国化学快报（英文版）

基　　金：support from the Collaborative Research Fund (No.C2011-21GF);Guangdong Province Basic and Applied Basic Research Foundation (No.2021B1515120051)。

摘　　要：Parkinson's disease(PD) is an aging-associated neurodegenerative movement disorder with increasing morbidity and mortality rates.The current gold standard for diagnosing PD is clinical evaluation,which is often challenging and inaccurate.Metabolomics and lipidomics approaches have been extensively applied because of their potential in discovering valuable biomarkers for medical diagnostics.Here,we used comprehensive untargeted metabolomics and lipidomics methodologies based on liquid chromatographymass spectrometry to evaluate metabolic abnormalities linked with PD.Two well-characterized cohorts of288 plasma samples(143 PD patients and 145 control subjects in total) were used to examine metabolic alterations and identify diagnostic biomarkers.Unbiased multivariate and univariate studies were combined to identify the promising metabolic signatures,based on which the discriminant models for PD were established by integrating multiple machine learning algorithms.A 6-biomarker predictive model was constructed based on the omics profile in the discovery cohort,and the discriminant performance of the biomarker panel was evaluated with an accuracy over 81.6% both in the discovery cohort and validation cohort.The results indicated that PC(40:7),eicosatrienoic acid were negatively correlated with severity of PD,and pentalenic acid,PC(40:6p) and aspartic acid were positively correlated with severity of PD.In summary,we developed a multi-metabolite predictive model which can diagnose PD with over81.6% accuracy based on this unique metabolic signature.Future clinical diagnosis of PD may benefit from the biomarker panel reported in this study.

关 键 词：Parkinson's disease Metabolomics LIPIDOMICS Machine learning BIOMARKER 

分 类 号：R742.5[医药卫生—神经病学与精神病学]